Cha Bio&Diostech, Pluristem Therapeutics deal

Pluristem's Pluristem Ltd. subsidiary issued to Cha 2.5 million shares at $4.16 in exchange for about 1 million shares of Cha common stock under a June deal to develop and commercialize PLX-PAD in South Korea to treat critical limb ischemia (CLI) and intermediate claudication. The price is a 26% premium to Pluristem's close of $3.29 on Dec. 16, before the deal was finalized. PLX-PAD cells are allogeneic, placental-derived expanded (PLX) cells (see BioCentury, June 10, 2013 & July 15, 2013). ...